MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2026)

MoonLake Immunotherapeutics' Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at $77000.0 for Q1 2026.

• On a quarterly basis, Income from Non-Controlling Interests rose 112.52% year-over-year to $77000.0 in Q1 2026; TTM through Mar 2026 was -$4.4 million, a 399.12% decrease from a year earlier, with the FY2025 full-year figure at -$5.1 million, down 290.73% from the prior year.
• Income from Non-Controlling Interests grew to $77000.0 in Q1 2026 per MLTX's latest filing, from -$2.7 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $9.4 million in Q4 2023 and bottomed at -$5.3 million in Q2 2022.
• The 5-year median for Income from Non-Controlling Interests is $50736.0 (2023), against an average of $320810.7.
• Across the five-year window, Income from Non-Controlling Interests soared 4363.67% in 2023 and sank 437.91% in 2025, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at $639890.0 in 2022, then surged by 1368.78% to $9.4 million in 2023, then slumped by 76.84% to $2.2 million in 2024, then sank by 224.53% to -$2.7 million in 2025, then soared by 102.84% to $77000.0 in 2026.
• Per Business Quant, the three latest MLTX Income from Non-Controlling Interests figures stand at $77000.0 (Q1 2026), -$2.7 million (Q4 2025), and -$965000.0 (Q3 2025).